PharmAla Donates MDMA for Fibromyalgia Trial in Major U.S. Research Collaboration

PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) has provided an update.

PharmAla Biotech has signed a drug donation agreement with Spaulding Rehabilitation, part of the Mass General Brigham system, to supply its LaNeo MDMA at no cost for a clinical trial investigating MDMA-assisted therapy in fibromyalgia patients. In return, PharmAla will receive a license to the study results, which it can use for public applications such as potential regulatory submissions, while Spaulding retains first publication rights and control over independent intellectual property.

The study, led by Principal Investigator Vitaly Napadow in Boston, will use hyperscan neuroimaging to explore how MDMA-assisted therapy affects brain mechanisms related to pain relief and interpersonal dynamics in fibromyalgia, a chronic condition affecting about 4 million U.S. adults. The collaboration extends PharmAla’s clinical research footprint beyond PTSD into pain and complex, treatment-resistant conditions, potentially strengthening its position in psychedelic-derived therapeutics and expanding the evidence base for MDMA’s analgesic and neuromodulatory effects.

The most recent analyst rating on (TSE:MDMA) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on PharmAla Biotech Holdings, Inc. stock, see the TSE:MDMA Stock Forecast page.

Spark’s Take on TSE:MDMA Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDMA is a Neutral.

The score is held back primarily by weak financial performance: deteriorating profitability, negative gross profit, and ongoing cash burn despite improving revenue. Technicals are mixed with only modest near-term strength, and valuation is constrained by losses (negative P/E) with no dividend support.

To see Spark’s full report on TSE:MDMA stock, click here.

More about PharmAla Biotech Holdings, Inc.

PharmAla Biotech Holdings Inc. is a biotechnology company specializing in the research, development, and manufacturing of MDXX-class molecules, including MDMA. The company focuses on alleviating the global shortage of clinical-grade MDMA for trials and selected commercial uses, while also advancing novel MDMA-based therapeutics for emerging indications.

Average Trading Volume: 135,187

Technical Sentiment Signal: Sell

Current Market Cap: C$10.89M

For an in-depth examination of MDMA stock, go to TipRanks’ Overview page.